Literature DB >> 12134611

The epidemic of esophageal adenocarcinoma.

Hashem B el-Serag1.   

Abstract

The incidence and mortality related to esophageal adenocarcinoma (EAC) have been increasing in the United States, several European countries, and Oceania for the past 2 to 3 decades. Survival remains dismal, with little improvement during the same time period. Variations in the coding, classification, and detection of gastroesophageal malignancy may have contributed partially to the observed trends. Remarkable differences related to gender, ethnicity, and geography characterize the epidemiology of EAC. Gastroesophageal reflux disease (GERD) is the main risk factor for Barrett's esophagus, which is the only known precursor lesion for EAC. Several risk factors that promote the development of GERD and/or Barrett's esophagus have been proposed to explain these rising trends; these factors include the declining rates of Helicobacter pylori infection, obesity, dietary factors, and certain drugs.

Entities:  

Mesh:

Year:  2002        PMID: 12134611     DOI: 10.1016/s0889-8553(02)00016-x

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  38 in total

1.  Association of insulin and insulin-like growth factors with Barrett's oesophagus.

Authors:  Katarina B Greer; Cheryl L Thompson; Lacie Brenner; Beth Bednarchik; Dawn Dawson; Joseph Willis; William M Grady; Gary W Falk; Gregory S Cooper; Li Li; Amitabh Chak
Journal:  Gut       Date:  2011-09-19       Impact factor: 23.059

2.  The role of integrated F-18-FDG-PET scanning in the detection of M1 disease in oesophageal adenocarcinoma and impact on clinical management.

Authors:  Soumil Vyas; Sheraz R Markar; Lydia Iordanidou; Samantha Read; David Stoker; Majid Hashemi; Ian Mitchell; Mark Winslet; Jamshed Bomanji
Journal:  J Gastrointest Surg       Date:  2011-10-01       Impact factor: 3.452

3.  CagA in Barrett's oesophagus in Colombia, a country with a high prevalence of gastric cancer.

Authors:  M Kudo; O Gutierrez; H M T El-Zimaity; H Cardona; Z Z Nurgalieva; J Wu; D Y Graham
Journal:  J Clin Pathol       Date:  2005-03       Impact factor: 3.411

Review 4.  Endoscopic therapy for Barrett's oesophagus.

Authors:  H Barr; N Stone; B Rembacken
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

5.  Dietary intake and the risk of gastro-oesophageal reflux disease: a cross sectional study in volunteers.

Authors:  H B El-Serag; J A Satia; L Rabeneck
Journal:  Gut       Date:  2005-01       Impact factor: 23.059

6.  Targeting key signalling pathways in oesophageal adenocarcinoma: a reality for personalised medicine?

Authors:  Richard R Keld; Yeng S Ang
Journal:  World J Gastroenterol       Date:  2011-06-21       Impact factor: 5.742

7.  Age and sex differences in the incidence of esophageal adenocarcinoma: results from the Surveillance, Epidemiology, and End Results (SEER) Registry (1973-2008).

Authors:  L N Mathieu; N F Kanarek; H-L Tsai; C M Rudin; M V Brock
Journal:  Dis Esophagus       Date:  2013-10-07       Impact factor: 3.429

8.  Different redox states in malignant and nonmalignant esophageal epithelial cells and differential cytotoxic responses to bile acid and honokiol.

Authors:  Gang Chen; Julie Izzo; Yusuke Demizu; Feng Wang; Sushovan Guha; Xifeng Wu; Mein-Chie Hung; Jaffer A Ajani; Peng Huang
Journal:  Antioxid Redox Signal       Date:  2009-05       Impact factor: 8.401

9.  AXL mediates TRAIL resistance in esophageal adenocarcinoma.

Authors:  Jun Hong; Abbes Belkhiri
Journal:  Neoplasia       Date:  2013-03       Impact factor: 5.715

10.  Gastroesophageal reflux disease: medical or surgical treatment?

Authors:  Theodore Liakakos; George Karamanolis; Paul Patapis; Evangelos P Misiakos
Journal:  Gastroenterol Res Pract       Date:  2009-12-31       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.